Microassay for measurement of binding of radiolabelled ligands to cell surface molecules.

J. Woof,D. Burton

DOI: https://doi.org/10.1016/0022-1759(88)90128-7

1988-07-22

Abstract:

What problem does this paper attempt to address?

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines

David Hodgson,Yi Liu,Louise Carolan,Siddhartha Mahanty,Kanta Subbarao,Sheena Sullivan,Annette Fox,Adam J Kucharski

DOI: https://doi.org/10.1101/2024.07.11.24310221

2024-07-11

Abstract:Vaccination against COVID-19 has been pivotal in reducing the global burden of the disease. However, Phase III trial results and observational studies underscore differences in efficacy across vaccine technologies and dosing regimens. Notably, mRNA vaccines have exhibited superior effectiveness compared to Adenovirus (AdV) vaccines, especially with extended dosing intervals. Using in-host mechanistic modelling, this study elucidates these variations and unravels the biological mechanisms shaping the immune responses at the cellular level. We used data on the change in memory B cells, plasmablasts, and antibody titres after the second dose of a COVID-19 vaccine for Australian healthcare workers. Alongside this dataset, we constructed a kinetic model of humoral immunity which jointly captured the dynamics of multiple immune markers, and integrated hierarchical effects into this kinetics model, including age, dosing schedule, and vaccine type. Our analysis estimated that mRNA vaccines induced 2.1 times higher memory B cell proliferation than AdV vaccines after adjusting for age, interval between doses and priming dose. Additionally, extending the duration between the second vaccine dose and priming dose beyond 28 days boosted neutralising antibody production per plasmablast concentration by 30%. We also found that antibody responses after the second dose were more persistent when mRNA vaccines were used over AdV vaccines and for longer dosing regimens. Reconstructing in-host kinetics in response to vaccination could help optimise vaccine dosing regimens, improve vaccine efficacy in different population groups, and inform the design of future vaccines for enhanced protection against emerging pathogens.
Bivalent COVID-19 vaccines boost the capacity of pre-existing SARS-CoV-2-specific memory B cells to cross-recognize Omicron subvariants

Holly A. Fryer,Daryl Geers,Lennert Gommers,Luca M. Zaeck,Ngoc H. Tan,Bernadette Jones-Freeman,Abraham Goorhuis,Douwe F. Postma,Leo G. Visser,P. Mark Hogarth,Marion P. G. Koopmans,Corine H. GeurtsvanKessel,Robyn E. O’Hehir,P. Hugo M. van der Kuy,Rory D. de Vries,Menno C. van Zelm

DOI: https://doi.org/10.1101/2024.03.20.585861

2024-03-22

Abstract:Bivalent COVID-19 vaccines comprising ancestral Wuhan-Hu-1 (WH1) and the Omicron BA.1 or BA.5 subvariant elicit enhanced serum antibody responses to emerging Omicron subvariants. We characterized the memory B-cell (Bmem) response following a fourth dose with a BA.1 or BA.5 bivalent vaccine, and compared the immunogenicity with a WH1 monovalent fourth dose. Healthcare workers previously immunized with mRNA or adenoviral vector monovalent vaccines were sampled before and one-month after a monovalent, BA.1 or BA.5 bivalent fourth dose COVID-19 vaccine. RBD-specific Bmem were quantified with an in-depth spectral flow cytometry panel including recombinant RBD proteins of the WH1, BA.1, BA.5, BQ.1.1, and XBB.1.5 variants. All recipients had slightly increased WH1 RBD-specific Bmem numbers. Recognition of Omicron subvariants was not enhanced following monovalent vaccination, while both bivalent vaccines significantly increased WH1 RBD-specific Bmem cross-recognition of all Omicron subvariants tested by flow cytometry. Thus, Omicron-based bivalent vaccines can improve recognition of descendent Omicron subvariants by pre-existing, WH1-specific Bmem, beyond that of a conventional, monovalent vaccine. This provides new insights into the capacity of variant-based mRNA booster vaccines to improve immune memory against emerging SARS-CoV-2 variants.

Immunology
Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines

Yi Liu,Stephany Sánchez-Ovando,Louise Carolan,Leslie Dowson,Arseniy Khvorov,A. Jessica Hadiprodjo,Yeu Yang Tseng,Catherine Delahunty,Ameneh Khatami,Marion Macnish,Sonia Dougherty,Michelle Hagenauer,Kathryn E. Riley,Ajay Jadhav,Joanne Harvey,Marti Kaiser,Suja Mathew,David Hodgson,Vivian Leung,Kanta Subbarao,Allen C. Cheng,Kristine Macartney,Archana Koirala,Helen Marshall,Julia Clark,Christopher C. Blyth,Peter Wark,Adam J. Kucharski,Sheena G. Sullivan,Annette Fox

DOI: https://doi.org/10.1016/j.vaccine.2023.10.034

IF: 4.169

2023-10-30

Vaccine

Abstract:Both vector and mRNA vaccines were an important part of the response to the COVID-19 pandemic and may be required in future outbreaks and pandemics. The aim of this study was to validate whether immunogenicity differs for adenoviral vectored (AdV) versus mRNA vaccines against SARS-CoV-2, and to investigate how anti-vector immunity and B cell dynamics modulate immunogenicity. We enrolled SARS-CoV-2 infection-naïve health care workers who had received two doses of either AdV AZD1222 (n = 184) or mRNA BNT162b2 vaccine (n = 274) between April and October 2021. Blood was collected at least once, 10–48 days after vaccine dose 2 for antibody and B cell analyses. Median ages were 42 and 39 years, for AdV and mRNA vaccinees, respectively. Surrogate virus neutralization test (sVNT) and spike binding antibody titres were a median of 4.2 and 2.2 times lower, respectively, for AdV compared to mRNA vaccinees (p < 0.001). Median percentages of memory B cells that recognized fluorescent-tagged spike and RBD were 2.9 and 8.3 times lower, respectively for AdV compared to mRNA vaccinees. Titres of IgG reactive with human adenovirus type 5 hexon protein rose a median of 2.2-fold after AdV vaccination but were not correlated with anti-spike antibody titres. Together the results show that mRNA induced substantially more sVNT antibody than AdV vaccine, which reflected greater B cell expansion and targeting of the RBD rather than an attenuating effect of anti-vector antibodies. ClinicalTrials.gov Identifier: NCT05110911.

immunology,medicine, research & experimental
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants

Holly A Fryer,Daryl Geers,Lennert Gommers,Luca M Zaeck,Ngoc H Tan,Bernadette Jones-Freeman,Abraham Goorhuis,Douwe F Postma,Leo G Visser,P Mark Hogarth,Marion P G Koopmans,Corine H GeurtsvanKessel,Robyn E O'Hehir,P Hugo M van der Kuy,Rory D de Vries,Menno C van Zelm

DOI: https://doi.org/10.1016/j.jinf.2024.106246

Abstract:Bivalent COVID-19 vaccines comprising ancestral Wuhan-Hu-1 (WH1) and the Omicron BA.1 or BA.5 subvariant elicit enhanced serum antibody responses to emerging Omicron subvariants. Here, we characterized the RBD-specific memory B cell (Bmem) response following a fourth dose with a BA.1 or BA.5 bivalent vaccine, in direct comparison with a WH1 monovalent fourth dose. Healthcare workers previously immunized with mRNA or adenoviral vector monovalent vaccines were sampled before and one month after a fourth dose with a monovalent or a BA.1 or BA.5 bivalent vaccine. Serum neutralizing antibodies (NAb) were quantified, as well as RBD-specific Bmem with an in-depth spectral flow cytometry panel including recombinant RBD proteins of the WH1, BA.1, BA.5, BQ.1.1, and XBB.1.5 variants. Both bivalent vaccines elicited higher NAb titers against Omicron subvariants compared to the monovalent vaccine. Following either vaccine type, recipients had slightly increased WH1 RBD-specific Bmem numbers. Both bivalent vaccines significantly increased WH1 RBD-specific Bmem binding of all Omicron subvariants tested by flow cytometry, while recognition of Omicron subvariants was not enhanced following monovalent vaccination. IgG1+ Bmem dominated the response, with substantial IgG4+ Bmem only detected in recipients of an mRNA vaccine for their primary dose. Thus, Omicron-based bivalent vaccines can significantly boost NAb and Bmem specific for ancestral WH1 and Omicron variants and improve recognition of descendent subvariants by pre-existing, WH1-specific Bmem beyond that of a monovalent vaccine. This provides new insights into the capacity of variant-based mRNA booster vaccines to improve immune memory against emerging SARS-CoV-2 variants and potentially protect against severe disease. ONE-SENTENCE SUMMARY: Omicron BA.1 and BA.5 bivalent COVID-19 boosters, used as a fourth dose, increase RBD-specific Bmem cross-recognition of Omicron subvariants, both those encoded by the vaccines and antigenically distinct subvariants, further than a monovalent booster.
Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines

Astrid K. Hvidt,Eva A. M. Baerends,Ole S. Søgaard,Nina B. Stærke,Dorthe Raben,Joanne Reekie,Henrik Nielsen,Isik S. Johansen,Lothar Wiese,Thomas L. Benfield,Kasper K. Iversen,Ahmed B. Mustafa,Maria R. Juhl,Kristine T. Petersen,Sisse R. Ostrowski,Susan O. Lindvig,Line D. Rasmussen,Marianne H. Schleimann,Sidsel D. Andersen,Anna K. Juhl,Lisa L. Dietz,Signe R. Andreasen,Jens Lundgren,Lars Østergaard,Martin Tolstrup,

DOI: https://doi.org/10.3389/fmed.2022.994160

IF: 3.9

2022-10-03

Frontiers in Medicine

Abstract:The SARS-CoV-2 pandemic has, as of July 2022, infected more than 550 million people and caused over 6 million deaths across the world. COVID-19 vaccines were quickly developed to protect against severe disease, hospitalization and death. In the present study, we performed a direct comparative analysis of four COVID-19 vaccines: BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), ChAdOx1 (Oxford/AstraZeneca) and Ad26.COV2.S (Johnson & Johnson/Janssen), following primary and booster vaccination. We focused on the vaccine-induced antibody-mediated immune response against multiple SARS-CoV-2 variants: wildtype, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and B.1.1.529 (Omicron). The analysis included the quantification of total IgG levels against SARS-CoV-2 Spike, as well as the quantification of antibody neutralization titers. Furthermore, the study assessed the high-throughput ACE2 competition assay as a surrogate for the traditional pseudovirus neutralization assay. The results demonstrated marked differences in antibody-mediated immune responses. The lowest Spike-specific IgG levels and antibody neutralization titers were induced by one dose of the Ad26.COV2.S vaccine, intermediate levels by two doses of the BNT162b2 vaccine, and the highest levels by two doses of the mRNA-1273 vaccine or heterologous vaccination of one dose of the ChAdOx1 vaccine and a subsequent mRNA vaccine. The study also demonstrated that accumulation of SARS-CoV-2 Spike protein mutations was accompanied by a marked decline in antibody neutralization capacity, especially for B.1.1.529. Administration of a booster dose was shown to significantly increase Spike-specific IgG levels and antibody neutralization titers, erasing the differences between the vaccine-induced antibody-mediated immune response between the four vaccines. The findings of this study highlight the importance of booster vaccines and the potential inclusion of future heterologous vaccination strategies for broad protection against current and emerging SARS-CoV-2 variants.

medicine, general & internal
Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens

Chia-Lo Ho,Li-Chen Yen,Hong-Wei Huang,Chun-Chi Lu,Yi-Jen Hung,Ching-Len Liao,Chin-Mao Hung,Kuo-Chou Chiu

DOI: https://doi.org/10.3389/fimmu.2024.1340645

IF: 7.3

2024-03-12

Frontiers in Immunology

Abstract:Background: The emergence of SARS-CoV-2 variants has raised concerns about the sustainability of vaccine-induced immunity. Little is known about the long-term humoral responses and spike-specific T cell memory to Omicron variants, with specific attention to BA.4/5, BQ.1.1, and XBB.1. Methods: We assessed immune responses in 50 uninfected individuals who received varying three-dose vaccination combinations (2X AstraZeneca + 1X Moderna, 1X AstraZeneca + 2X Moderna, and 3X Moderna) against wild-type (WT) and Omicron variants at eight months post-vaccination. The serum antibody titers were analyzed by enzyme-linked immunosorbent assays (ELISA), and neutralizing activities were examined by pseudovirus and infectious SARS-CoV-2 neutralization assays. T cell reactivities and their memory phenotypes were determined by flow cytometry. Results: We found that RBD-specific antibody titers, neutralizing activities, and CD4+ T cell reactivities were reduced against Omicron variants compared to WT. In contrast, CD8+ T cell responses, central memory, effector memory, and CD45RA+ effector memory T cells remained unaffected upon stimulation with the Omicron peptide pool. Notably, CD4+ effector memory T cells even exhibited a higher proportion of reactivity against Omicron variants. Furthermore, participants who received three doses of the Moderna showed a more robust response regarding neutralization and CD8+ T cell reactions than other three-dose vaccination groups. Conclusion: Reduction of humoral and CD4+ T cell responses against Omicron variants in vaccinees suggested that vaccine effectiveness after eight months may not have sufficient protection against the new emerging variants, which provides valuable information for future vaccination strategies such as receiving BA.4/5 or XBB.1-based bivalent vaccines.

immunology
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity

Rüdiger Groß,Michelle Zanoni,Alina Seidel,Carina Conzelmann,Andrea Gilg,Daniela Krnavek,Sümeyye Erdemci-Evin,Benjamin Mayer,Markus Hoffmann,Stefan Pöhlmann,Alexandra Beil,Joris Kroschel,Bernd Jahrsdörfer,Hubert Schrezenmeier,Frank Kirchhoff,Jan Münch,Janis A. Müller

DOI: https://doi.org/10.1101/2021.05.30.21257971

2021-06-01

Abstract:Abstract Heterologous COVID-19 vaccination regimens combining vector- and mRNA-based vaccines are already administered, but data on solicited adverse reactions, immunological responses and elicited protection are limited. We aimed to evaluate the reactogenicity, humoral and cellular immune responses towards different SARS-CoV-2 variants after a heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination and analyzed a cohort of 26 individuals aged 25-46 (median 30.5) years that received a ChAdOx1 nCoV-19 prime followed by a BNT162b2 boost after an 8- week interval. Self-reported solicited symptoms after ChAdOx1 nCoV-19 prime were in line with previous reports and less severe after the BNT162b2 boost. Antibody titers increased significantly over time resulting in strong neutralization titers two weeks after the BNT162b2 boost. Neutralizing activity against the prevalent strain B.1.1.7 (Alpha) and immune-evading VOC B.1.351 (Beta) was ∼4-fold higher than in individuals receiving homologous BNT162b2 vaccination. No difference was seen in neutralization of VOI B.1.617 (Kappa). In addition, the heterologous vaccination induced CD4+ and CD8+ T cells reactive to SARS-CoV-2 spike peptides of all analyzed variants; Wuhan-Hu-1, B.1.1.7, B.1.351, and P.1 (Gamma). In conclusion, heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination regimen is not associated with serious adverse events and results in a potent humoral immune response and elicits T cell reactivity. Variants B.1.1.7, B.1.351 and B.1.617.1 are potently neutralized by sera of all participants and reactive T cells recognize spike peptides of all tested variants. These results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations.
Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells

Kilian A. Wietschel,Kevin Fechtner,Elmer Antileo,Goran Abdurrahman,Chiara A. Drechsler,Michelle Kudzayi Makuvise,Ruben Rose,Mathias Voß,Andi Krumbholz,Stephan Michalik,Stefan Weiss,Lena Ulm,Philipp Franikowski,Helmut Fickenscher,Barbara M. Bröker,Dina Raafat,Silva Holtfreter

DOI: https://doi.org/10.3389/fimmu.2024.1382911

IF: 7.3

2024-05-15

Frontiers in Immunology

Abstract:Introduction: COVID-19 vaccines are highly effective in inducing protective immunity. While the serum antibody response to COVID-19 vaccination has been studied in depth, our knowledge of the underlying plasmablast and memory B cell (Bmem) responses is still incomplete. Here, we determined the antibody and B cell response to COVID-19 vaccination in a naïve population and contrasted it with the response to a single influenza vaccination in a primed cohort. In addition, we analyzed the antibody and B cell responses against the four endemic human coronaviruses (HCoVs). Methods: Measurement of specific plasma IgG antibodies was combined with functional analyses of antibody-secreting plasmablasts and Bmems. SARS-CoV-2- and HCoV-specific IgG antibodies were quantified with an in-house bead-based multiplexed immunoassay. Results: The antibody and B cell responses to COVID-19 vaccination reflected the kinetics of a prime-boost immunization, characterized by a slow and moderate primary response and a faster and stronger secondary response. In contrast, the influenza vaccinees possessed robust immune memory for the vaccine antigens prior to vaccination, and the recall vaccination moderately boosted antibody production and Bmem responses. Antibody levels and Bmem responses waned several months after the 2 nd COVID-19 vaccination, but were restored upon the 3 rd vaccination. The COVID-19 vaccine-induced antibodies mainly targeted novel, non-cross-reactive S1 epitopes of the viral spike protein, while cross-reactive S2 epitopes were less immunogenic. Booster vaccination not only strongly enhanced neutralizing antibodies against an original SARS-CoV-2 strain, but also induced neutralizing antibodies against the Omicron BA.2 variant. We observed a 100% plasma antibody prevalence against the S1 subunits of HCoVs, which was not affected by vaccination. Discussion: Overall, by complementing classical serology with a functional evaluation of plasmablasts and memory B cells we provide new insights into the specificity of COVID-19 vaccine-induced antibody and B cell responses.

immunology
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Rishi R. Goel,Mark M. Painter,Sokratis A. Apostolidis,Divij Mathew,Wenzhao Meng,Aaron M. Rosenfeld,Kendall A. Lundgreen,Arnold Reynaldi,David S. Khoury,Ajinkya Pattekar,Sigrid Gouma,Leticia Kuri-Cervantes,Philip Hicks,Sarah Dysinger,Amanda Hicks,Harsh Sharma,Sarah Herring,Scott Korte,Amy E. Baxter,Derek A. Oldridge,Josephine R. Giles,Madison E. Weirick,Christopher M. McAllister,Moses Awofolaju,Nicole Tanenbaum,Elizabeth M. Drapeau,Jeanette Dougherty,Sherea Long,Kurt D’Andrea,Jacob T. Hamilton,Maura McLaughlin,Justine C. Williams,Sharon Adamski,Oliva Kuthuru,The UPenn COVID Processing Unit‡,Ian Frank,Michael R. Betts,Laura A. Vella,Alba Grifoni,Daniela Weiskopf,Alessandro Sette,Scott E. Hensley,Miles P. Davenport,Paul Bates,Eline T. Luning Prak,Allison R. Greenplate,E. John Wherry,S. Adamski,Z. Alam,M. M. Addison,K. T. Byrne,A. Chandra,H. C. Descamps,N. Han,Y. Kaminskiy,S. C. Kammerman,J. Kim,A. R. Greenplate,J. T. Hamilton,N. Markosyan,J. Han Noll,D. K. Omran,A. Pattekar,E. Perkey,E. M. Prager,D. Pueschl,A. Rennels,J. B. Shah,J. S. Shilan,N. Wilhausen,A. N. Vanderbeck,

DOI: https://doi.org/10.1126/science.abm0829

IF: 56.9

2021-12-03

Science

Abstract:Immune memory after vaccination Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven highly effective at preventing severe COVID-19. However, the evolution of viral variants, and waning antibody levels over time, raise questions regarding the longevity of vaccine-induced immune protection. Goel et al . examined B and T lymphocyte responses in individuals who received SARS-CoV-2 messenger RNA vaccines. They performed a 6-month longitudinal study of individuals who never had SARS-CoV-2 infection compared with people who had recovered from SARS-CoV-2. Humoral and cellular immune memory was observed in vaccinated individuals, as were functional immune responses against the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) viral variants. Analysis of T cell activity suggested that robust cellular immune memory may prevent hospitalization by limiting the development of severe disease. —PNK

multidisciplinary sciences
Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees

Pei Yu,Zijian Liu,Zhuoqi Zhu,Jiaqing Yang,Min Deng,Mingxiao Chen,Changchun Lai,Weiya Kong,Shilong Xiong,Li Wan,Weikang Mai,Lu Chen,Shahzad Akbar Khan,Jianfeng Ruan,An Kang,Xuguang Guo,Qiang Zhou,Wenrui Li,Zheng Chen,Yuemei Liang,Pingchao Li,Lei Zhang,Tianxing Ji,Yu

DOI: https://doi.org/10.1016/j.virs.2022.12.008

IF: 6.947

2023-01-03

Virologica Sinica

Abstract:Highlights • Ad5-nCoV booster and Omicron breakthrough infection (OBI) induced comparable SARS-CoV-2 specific antibody level. • The main SARS-CoV-2 specific IgG subclass in vaccine boosted HVs and OBI patients were IgG1 and IgG3. • Ad5-nCoV booster and OBI induced comparable SARS-CoV-2 specific T cells immunity. • Omicron specific MBCs was higher in OBI patients compared to homologous and heterologous vaccine boosted people. Homologous booster, heterologous booster, and Omicron variants breakthrough infection (OBI) could improve the humoral immunity against Omicron variants. Questions concerning about memory B cells (MBCs) and T cells immunity against Omicron variants, features of long-term immunity, after booster and OBI, needs to be explored. Here, comparative analysis demonstrate antibody and T cell immunity against ancestral strain, Delta and Omicron variants in Omicron breakthrough infected patients (OBIPs) are comparable to that in Ad5-nCoV boosted healthy volunteers (HVs), higher than that in inactivated vaccine (InV) boosted HVs. However, memory B cells (MBCs) immunity against Omicron variants was highest in OBIPs, followed by Ad5-nCoV boosted and InV boosted HVs. OBIPs and Ad5-nCoV boosted HVs have higher classical MBCs and activated MBCs, and lower naïve MBCs and atypical MBCs relative to both vaccine boosted HVs. Collectively, these data indicate Omicron breakthrough infection elicit higher MBCs and T cells against SARS-CoV-2 especially Omicron variants relative to homologous InV booster and heterologous Ad5-nCoV booster.

virology
Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants

Hengchun Li,Chenchen Yang,Li Yin,Wenming Liu,Zhengyuan Zhang,Bo Liu,Xinxin Sun,Wenhao Liu,Zihan Lin,Zijian Liu,Ping He,Ying Feng,Chunhua Wang,Wei Wang,Suhua Guan,Qian Wang,Ling Chen,Pingchao Li

DOI: https://doi.org/10.1080/22221751.2024.2387447

2024-08-21

Emerging Microbes & Infections

Abstract:The continuous emergence of highly immune-evasive SARS-CoV-2 variants has challenged vaccine efficacy. A vaccine that can provide broad protection is desirable. We evaluated the immunogenicity of a series of monovalent and bivalent adenovirus-vectored vaccines containing the spikes of Wildtype (WT), Beta, Delta, Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.2.13, BA.3, BA.5, BQ.1.1, and XBB. Vaccination in mice using monovalent vaccines elicited the highest neutralizing titers against each self-matched strain, but against other variants were reduced 2− to 73-fold. A bivalent vaccine consisting of WT and BA.5 broadened the neutralizing breadth against pre-Omicron and Omicron subvariants except XBB. Among bivalent vaccines based on the strains before the emergence of XBB, a bivalent vaccine consisting of BA.2 and BA.5 elicited the most potent neutralizing antibodies against Omicron subvariants, including XBB. In mice primed with injected WT vaccine, intranasal booster with a bivalent vaccine containing XBB and BA.5 could elicit broad serum and respiratory mucosal neutralizing antibodies against all late Omicron subvariants, including XBB. In mice that had been sequentially vaccinated with WT and BA.5, intranasal booster with a monovalent XBB vaccine elicited greater serum and mucosal XBB neutralizing antibodies than bivalent vaccines containing XBB. Both monovalent and bivalent XBB vaccines induced neutralizing antibodies against EG.5. Unlike the antibody response, which is highly variant-specific, mice receiving either monovalent or bivalent vaccines elicited comparable T-cell responses against all variants. Furthermore, intranasal but not intramuscular booster induced antigen-specific lung resident T cells. This study provides insights into the design of the COVID-19 vaccine and vaccination strategies.

immunology,infectious diseases,microbiology
Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination

Nungruthai Suntronwong,Sitthichai Kanokudom,Thaksaporn Thatsanathorn,Thanunrat Thongmee,Natthinee Sudhinaraset,Nasamon Wanlapakorn,Yong Poovorawan

DOI: https://doi.org/10.1080/21645515.2023.2283916

2023-12-15

Abstract:Heterologous vaccination with inactivated vaccine followed by adenoviral vector-based vaccine has shown superiority in enhancing immune response compared to homologous primary series. However, data comparing immunity decline after a third booster following heterologous CoronaVac/ChAdOx-1nCov-19 has been limited. Here, we assessed neutralizing activity against omicron variant and T cell response at 3 months monitoring in 96 individuals who received ChAdOx-1nCov-19, BNT162b2, or mRNA-1273 as a third dose following heterologous CoronaVac/ChAdOx-1nCov-19. Comparing the antibody levels at 3 and 1 month(s) after the third booster, the results showed a persistence of anti-RBD IgG in all vaccine regimens, with the IgG level waning slower in the ChAdOx-1nCov-19 boosted group (geometric mean ratio (GMR): 0.64 (95%CI: 0.59-0.70)) compared to the BNT162b2 (0.34 (95%CI:0.31-0.38)) and mRNA-1273 boosted groups (0.32 (95%CI: 0.29-0.36)). Neutralizing activity against omicron BA.2 and BA.4/5 dropped by 1.2 to 1.5-fold but remained detectable, with the highest level observed in the mRNA-1273 group, followed by BNT162b2 and ChAdOx-1nCov-19 groups, respectively. Furthermore, the number of individuals with T cell reactivity decreased in BNT162b2 and mRNA-1273 groups, while it increased in ChAdOx-1nCov-19 group at 3-month post-boost compared to 1 month. Data on the durability of immune response could help comprehensively optimize the booster vaccine strategy.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang,Fabian Schmidt,Yiska Weisblum,Frauke Muecksch,Christopher O. Barnes,Shlomo Finkin,Dennis Schaefer-Babajew,Melissa Cipolla,Christian Gaebler,Jenna A. Lieberman,Thiago Y. Oliveira,Zhi Yang,Morgan E. Abernathy,Kathryn E. Huey-Tubman,Arlene Hurley,Martina Turroja,Kamille A. West,Kristie Gordon,Katrina G. Millard,Victor Ramos,Justin Da Silva,Jianliang Xu,Robert A. Colbert,Roshni Patel,Juan Dizon,Cecille Unson-O’Brien,Irina Shimeliovich,Anna Gazumyan,Marina Caskey,Pamela J. Bjorkman,Rafael Casellas,Theodora Hatziioannou,Paul D. Bieniasz,Michel C. Nussenzweig

DOI: https://doi.org/10.1038/s41586-021-03324-6

IF: 64.8

2021-02-10

Nature

Abstract:Here we report on the antibody and memory B cell responses in a cohort of 20 volunteers who received either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines1–4. Eight weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers. Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection5,6. However, activity against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin. Vaccine-elicited monoclonal antibodies (mAbs) potently neutralize SARS-CoV-2, targeting a number of different RBD epitopes in common with mAbs isolated from infected donors5–8. However, neutralization by 14 of the 17 most potent mAbs tested was reduced or abolished by either K417N, or E484K, or N501Y mutations. Notably, the same mutations were selected when recombinant vesicular stomatitis virus (rVSV)/SARS-CoV-2 S was cultured in the presence of the vaccine elicited mAbs. Taken together the results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid potential loss of clinical efficacy.

multidisciplinary sciences
Comparison of Antigen-Specific B Cell Responses Reveals Disparity in Immunogenicity and Memory B Cell Formation Across COVID-19 Vaccine Platforms

Chang Guo,Xin Chai,Maidaiti Baerlike,Yingping Liu,Yao Wang,Fei Shao,Qingrui Huang,Weiguo Zhang,Shan Cen,Yijie Dong,Yunlong Cao,Jinghua Yan,Xuyu Zhou,Zhaolin Hua,Baidong Hou

DOI: https://doi.org/10.1016/j.hlife.2024.09.002

2024-01-01

hLife

Abstract:Various vaccine technologies have been employed in the coronavirus disease 2019 (COVID-19) vaccines, including whole inactivated virus (WIV), recombinant protein, mRNA, and nanoparticle vaccines. To elucidate the cellular mechanisms underlying the immune responses elicited by different vaccines, we examined and compared antigen-specific B cell responses targeting the receptor-binding domain (RBD) of the viral spike protein. We found that the nanoparticle vaccine pathogen-like antigens-RBD (PLA-RBD) and the mRNA vaccine demonstrated superior immunogenicity compared to the WIV vaccine and the RBD-dimer, a recombinant protein vaccine. Interestingly, the WIV vaccine contains toll-like receptor ligands that enhance IgG2a/c class-switching. For the mRNA vaccine, although it induces robust germinal center responses and T follicular helper (Tfh) cells, it has limited ability to induce memory B cells and long-lived plasma cells. These results indicate that vaccine formats significantly influence both the quantity and quality of immune responses, providing valuable insights for the future development of vaccines.
Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern

Ryan P. McNamara,Jenny S. Maron,Julie Boucau,Vicky Roy,Nicholas E. Webb,Harry L. Bertera,Amy K. Barczak,The Positives Study Staff,Nicholas Franko,Jennifer K. Logue,Megan Kemp,Jonathan Z. Li,Ling Zhou,Ching-Lin Hsieh,Jason S. McLellan,Mark J. Siedner,Michael S. Seaman,Jacob E. Lemieux,Helen Y. Chu,Galit Alter

DOI: https://doi.org/10.1128/mbio.00902-23

IF: 6.4

2023-08-03

mBio

Abstract:ABSTRACT While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2–3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies.

microbiology
Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike

Wonyeong Jung,Dansu Yuan,Benjamin Kellman,Isabela Garrido da Silva Gonzalez,Ralf Clemens,Eveline Pipolo Milan,Eduardo Sprinz,José Cerbino Neto,Igor Smolenov,Galit Alter,Ryan P. McNamara,Sue Ann Costa Clemens

DOI: https://doi.org/10.1038/s41541-023-00791-y

2024-01-07

npj Vaccines

Abstract:With the continued emergence of variants of concern, the global threat of COVID-19 persists, particularly in low- and middle-income countries with limited vaccine access. Protein-based vaccines, such as SCB-2019, can be produced on a large scale at a low cost while antigen design and adjuvant use can modulate efficacy and safety. While effective humoral immunity against SARS-CoV-2 variants has been shown to depend on both neutralization and Fc-mediated immunity, data on the effectiveness of protein-based vaccines with enhanced Fc-mediated immunity is limited. Here, we assess the humoral profile, including antibody isotypes, subclasses, and Fc receptor binding generated by a boosting with a recombinant trimer-tag protein vaccine SCB-2019. Individuals who were primed with 2 doses of the ChAdOx1 vaccine were equally divided into 4 groups and boosted with following formulations: Group 1: 9 μg SCB-2019 and Alhydrogel; Group 2: 9 μg SCB-2019, CpG 1018, and Alhydrogel; Group 3: 30 μg SCB-2019, CpG 1018, and Alhydrogel; Group 4: ChAdOx1. Group 3 showed enhanced antibody FcγR binding against wild-type and variants compared to Groups 1 and 2, showing a dose-dependent enhancement of immunity conferred by the SCB-2019 vaccine. Moreover, from day 15 after vaccination, Group 3 exhibited higher IgG3 and FcγR binding across variants of concerns, including Omicron and its subvariants, compared to the ChAdOx1-boosted individuals. Overall, this highlights the potential of SCB-2019 as a cost-efficient boosting regimen effective across variants of concerns.

immunology,medicine, research & experimental
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Georgia Deliyannis,Chinn Yi Wong,Paula Ellenberg,Tim Smith,Marianne Gillard,Ester Lopez,Julie McAuley,Chee Wah Tan,Weiguang Zeng,Mason Littlejohn,Runhong Zhou,Jasper Fuk-Woo Chan,Richard Bowen,Elizabeth Vincan,Joseph Torresi,Katherine Kedzierska,Kanta Subbarao,Marc Pellegrini,Trent Munro,Terry Nolan,Steven Rockman,Nicholas A. Gherardin,Samantha L. Grimley,James P. Cooney,Samuel J. Redmond,Kathryn C. Davidson,Francesca L. Mordant,Jing J. Wang,Zhi-wei Chen,Airn E. Hartwig,Jason M. Mackenzie,Colin W. Pouton,Tom P. Gordon,Lin-fa Wang,Stephen J. Kent,Adam K. Wheatley,Sharon R. Lewin,Amy W. Chung,David C. Jackson,Damian F.J. Purcell,Dale I. Godfrey

DOI: https://doi.org/10.1016/j.ebiom.2023.104574

IF: 11.205

2023-06-01

EBioMedicine

Abstract:BACKGROUND: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability during storage and transport, waning vaccine-induced immunity, and concerns about infrequent adverse events associated with existing vaccines.METHODS: We report on a protein subunit vaccine comprising the receptor-binding domain (RBD) of the ancestral SARS-CoV-2 spike protein, dimerised with an immunoglobulin IgG1 Fc domain. These were tested in conjunction with three different adjuvants: a TLR2 agonist R4-Pam2Cys, an NKT cell agonist glycolipid α-Galactosylceramide, or MF59® squalene oil-in-water adjuvant, using mice, rats and hamsters. We also developed an RBD-human IgG1 Fc vaccine with an RBD sequence of the immuno-evasive beta variant (N501Y, E484K, K417N). These vaccines were also tested as a heterologous third dose booster in mice, following priming with whole spike vaccine.FINDINGS: Each formulation of the RBD-Fc vaccines drove strong neutralising antibody (nAb) responses and provided durable and highly protective immunity against lower and upper airway infection in mouse models of COVID-19. The 'beta variant' RBD vaccine, combined with MF59® adjuvant, induced strong protection in mice against the beta strain as well as the ancestral strain. Furthermore, when used as a heterologous third dose booster, the RBD-Fc vaccines combined with MF59® increased titres of nAb against other variants including alpha, delta, delta+, gamma, lambda, mu, and omicron BA.1, BA.2 and BA.5.INTERPRETATION: These results demonstrated that an RBD-Fc protein subunit/MF59® adjuvanted vaccine can induce high levels of broadly reactive nAbs, including when used as a booster following prior immunisation of mice with whole ancestral-strain spike vaccines. This vaccine platform offers a potential approach to augment some of the currently approved vaccines in the face of emerging variants of concern, and it has now entered a phase I clinical trial.FUNDING: This work was supported by grants from the Medical Research Future Fund (MRFF) (2005846), The Jack Ma Foundation, National Health and Medical Research Council of Australia (NHMRC; 1113293) and Singapore National Medical Research Council (MOH-COVID19RF-003). Individual researchers were supported by an NHMRC Senior Principal Research Fellowship (1117766), NHMRC Investigator Awards (2008913 and 1173871), Australian Research Council Discovery Early Career Research Award (ARC DECRA; DE210100705) and philanthropic awards from IFM investors and the A2 Milk Company.

medicine, research & experimental
Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

Dennis Schaefer-Babajew,Zijun Wang,Frauke Muecksch,Alice Cho,Maximilian Loewe,Melissa Cipolla,Raphael Raspe,Brianna Johnson,Marie Canis,Justin DaSilva,Victor Ramos,Martina Turroja,Katrina G. Millard,Fabian Schmidt,Leander Witte,Juan Dizon,Kai-Hui Yao,Thiago Y. Oliveira,Anna Gazumyan,Christian Gaebler,Paul D. Bieniasz,Theodora Hatziioannou,Marina Caskey,Michel C. Nussenzweig,Irina Shimelovich

DOI: https://doi.org/10.1038/s41586-022-05609-w

IF: 64.8

2022-12-07

Nature

Abstract:Feedback inhibition of humoral immunity by antibodies was first documented in 1909 1 . Subsequent work showed that, depending on the context, antibodies can enhance or inhibit immune responses 2,3 . However, little is known about how pre-existing antibodies influence the development of memory B cells. Here we examined the memory B cell response in individuals who received two high-affinity anti-SARS-CoV-2 monoclonal antibodies, and subsequently two doses of an mRNA vaccine 4-8 . We found that monoclonal antibody recipients produced antigen binding and neutralizing titers that were only fractionally lower than controls. In contrast, their memory B cells differed from controls in that they predominantly expressed low-affinity IgM antibodies that carried small numbers of somatic mutations and showed altered RBD target specificity consistent with epitope masking. Moreover, only 1 out of 77 anti-RBD memory antibodies tested neutralized the virus. The mechanism underlying these findings was examined in experiments in mice that showed that germinal centers (GCs) formed in the presence of the same antibodies were dominated by low-affinity B cells. Our results indicate that pre-existing high-affinity antibodies bias GC and memory B cell selection by two distinct mechanisms: (1) by lowering the activation threshold for B cells thereby permitting abundant lower-affinity clones to participate in the immune response, and (2) through direct masking of their cognate epitopes. This may in part explain the shifting target profile of memory antibodies elicited by booster vaccinations 9 .

multidisciplinary sciences
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M Folegatti,Katie J Ewer,Parvinder K Aley,Brian Angus,Stephan Becker,Sandra Belij-Rammerstorfer,Duncan Bellamy,Sagida Bibi,Mustapha Bittaye,Elizabeth A Clutterbuck,Christina Dold,Saul N Faust,Adam Finn,Amy L Flaxman,Bassam Hallis,Paul Heath,Daniel Jenkin,Rajeka Lazarus,Rebecca Makinson,Angela M Minassian,Katrina M Pollock,Maheshi Ramasamy,Hannah Robinson,Matthew Snape,Richard Tarrant,Merryn Voysey,Catherine Green,Alexander D Douglas,Adrian V S Hill,Teresa Lambe,Sarah C Gilbert,Andrew J Pollard,Oxford COVID Vaccine Trial Group

DOI: https://doi.org/10.1016/S0140-6736(20)31604-4

2020-08-15

Abstract:Background: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. Methods: We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 × 1010 viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA50, MNA80, and MNA90]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606. Findings: Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA80 and in 35 (100%) participants when measured in PRNT50. After a booster dose, all participants had neutralising activity (nine of nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R2=0·67 by Marburg VN; p<0·001). Interpretation: ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme. Funding: UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gießen-Marburg-Langen.
Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms

Yannic Bartsch,Xin Tong,Jaweon Kang,María José Avendaño,Eileen F. Serrano,Tamara García-Salum,Catalina Pardo-Roa,Arnoldo Riquelme,Rafael A. Medina,Galit Alter

DOI: https://doi.org/10.1101/2021.12.24.21268378

2021-12-27

Abstract:Abstract Despite the dramatic spread of Omicron globally, even among highly vaccinated populations, death rates have not increased concomitantly. These data argue that alternative immune mechanisms, beyond neutralization, may continue to confer protection against severe disease. Beyond their ability to bind and block infection, antibodies contribute to control and clearance of multiple infections via their ability to direct antiviral immunity via Fc-effector mechanisms. Thus, here we probed the ability of vaccine induced antibodies, across three COVID-19 vaccines, to drive Fc-effector activity against Omicron. Despite the significant loss of IgM, IgA and IgG binding to the Omicron Receptor Binding Domain (RBD) across BNT162b2, mRNA-1273, and CoronaVac vaccines, stable isotype binding was observed across all of these vaccines to the Omicron Spike. Compromised RBD binding IgG was accompanied by a significant loss of cross RBD-specific antibody Fcγ-receptor binding by the CoronaVac vaccine, but preservation of RBD-specific FcγR2a and Fcγ3a binding across the mRNA vaccines. Conversely, Spike-specific antibodies exhibited persistent binding to Fcγ-receptors, across all three vaccines, albeit higher binding was observed with the mRNA vaccines, marked by a selective preservation of FcγR2a and Fcγ3a binding antibodies. Thus, despite the significant to near complete loss of Omicron neutralization across several vaccine platforms against Omicron, vaccine induced Spike-specific antibodies continue to recognize the virus and recruit Fc-receptors pointing to a persistent capacity for extra-neutralizing antibodies to contribute Omicron disease attenuation.

Microassay for measurement of binding of radiolabelled ligands to cell surface molecules.

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines

Bivalent COVID-19 vaccines boost the capacity of pre-existing SARS-CoV-2-specific memory B cells to cross-recognize Omicron subvariants

Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines

Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants

Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines

Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees

Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants

Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Comparison of Antigen-Specific B Cell Responses Reveals Disparity in Immunogenicity and Memory B Cell Formation Across COVID-19 Vaccine Platforms

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern

Boosting with adjuvanted SCB-2019 elicits superior Fcγ-receptor engagement driven by IgG3 to SARS-CoV-2 spike

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms